TwoXar discovers $3.4m seed

Venture firm Andreessen Horowitz has named drug discover startup TwoXar as the first investment out of its new $200m biotech fund.

TwoXar will receive $3.4m in seed funding which also saw support from CLI Ventures and Stanford-StartX Fund, the university venturing fund investing Stanford endowment cash into graduates from the StartX incubator.

TwoXar is working on a platform, dubbed Duma, which uses data to match drugs and diseases, which can both generate new drug candidates and assess the potential efficacy of existing therapeutics.

Andrew Radin, CEO of TwoXar, said: “We are working to disrupt the economics of drug discovery and accelerate the delivery of more effective medicines to patients fighting rare and common illnesses.”